Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis

Published:2015-03-10 Issue: Volume:3 Page:e835
ISSN:2167-8359
Container-title:PeerJ
language:en
Short-container-title:

Author:

Palamaner Subash Shantha Ghanshyam¹²,Kumar Anita Ashok¹²,Sethi Mansha³,Khanna Rohit C.⁴,Pancholy Samir Bipin⁵

Affiliation:

1. The Wright Center for Graduate Medical Education, Scranton, PA, USA

2. The Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA

3. Temple University School of Medicine, Philadelphia, PA, USA

4. Allen Foster Research Centre for Community Eye Health, International Centre for Advancement of Rural Eye Care, L V Prasad Eye Institute, Hyderabad, India

5. Department of Medicine, The Commonwealth Medical College, Scranton, PA, USA

Publisher

PeerJ

Subject

General Agricultural and Biological Sciences,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://peerj.com/articles/835.pdf

Reference44 articles.

1. Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis;Aggarwal;Nephrology, Dialysis, Transplantation,2004

2. A low-molecular-weight heparin (kabi 2165, fragmin) in repeated use for haemodialysis: Prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin;Anastassiades;Nephrology, Dialysis, Transplantation,1990

3. A low molecular weight heparin (“fragmin”) for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin;Anastassiades;Clinical Nephrology,1989

4. Simplified citrate anticoagulation for high-flux hemodialysis;Apsner;American Journal of Kidney Diseases,2001

5. Randomised long-term comparison of tinzaparin and dalteparin in haemodialysis;Beijering;Clinical Drug Investigation,2003

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nierenersatztherapie bei akutem Nierenversagen;Die Nephrologie;2024-02-16

2. Anticoagulation for people receiving long-term haemodialysis;Cochrane Database of Systematic Reviews;2024-01-08

3. Bleeding Risk in Hemodialysis Patients;Seminars in Nephrology;2023-11

4. How to Ensure Patency of the Extracorporeal Circuit in Hemodialysis: Global Perspectives;Seminars in Nephrology;2023-11

5. Single-Bolus Tinzaparin Anticoagulation in Extended Hemodialysis Session: A Feasibility Study;Kidney360;2023-03-15